TEC16-Advanced Therapies: Differentiation, Regeneration and Cancer
Advanced Therapies and Biomedical Technologies / IBS-TEC16 / Consolidated

The group's research focuses on two main axes, regenerative medicine and experimental oncology, not only in the basic aspects, but also clearly translational and interdisciplinary, with application in diagnosis and therapeutic use to benefit the health of patients with highly prevalent diseases, such as degenerative diseases and cancer. This multi and interdisciplinary orientation is based on the use of knowledge in nanotechnology and nanomedicine to meet the above objectives.
Research lines
- Therapeutic application of adult and progenitor stem cells in pathologies
- 3D bioprinting of tumors, tumors-on-a-chip and metastasis-on-chip
- 3D bioprinting and biotin development and generation of natural and synthetic biomaterials with application of prevalent pathologies
- Liquid biopsy: identification of new biomarkers and extracellular vesicles characteristic of CSCs with prognostic and predictive value of response in cancer patients
- Development of bioreactors with application in regenerative medicine
- Development of preclinical models for new useful treatments in regenerative medicine and cancer.
- Development of biological nanosystems based on cell membranes (noghosts)
- Development of new medical devices for the treatment of cancer (ultrasound)
- Development of chemical platforms for the detection of nucleic acids
- Implementation of intelligent theranostic nanomedicines
- Implementation of a non-invasive integrated platform based on the use of bioinformatics, nanotechnology and graphene biosensors
- Integration of nanotechnology with dynamic chemistry as a diagnostic tool
- New natural and synthetic drugs selective against CSCs
- Organoids-on-a-chip
- Role of cancer stem cells (CSCs) and their microenvironment in tumor development.
- Cancer gene therapy: suicide genes and CAR-T systems for solid tumors
- Use of chimeric cytokines in cell differentiation
Research networks
- RICORS TERAV Advanced Therapies
Keywords
stem cells, cancer stem cells, 3D bioprinting, labs-on-chip, nanoparticles, nano-ghosts, teragnosis, exosomes, liquid biopsy, gene therapy, suicide genes, bioreactors, medical devices, dynamic chemistry, biosensors
Ana Belen Diaz Ruano
Ana Voltes Martinez
Jesus Ruiz Espigares
Laura Garrido Martin
Elisa Nygren Jimenez
PAULA PLEGUEZUELOS BELTRAN
MARIA BELEN TOLEDO CUTILLAS
Jesus Pena Martin
LAURA DE LARA PEÑA
Julia Lopez de Andres
Alba Hidalgo Ramirez
NIEVES CASILLAS RUIZ
Giselle Xavier Reis
ANDREA MORENO REVUELTA
Maria Dolores Gomez Capel
AITOR GONZALEZ TITOS
MARIA DEL CARMEN HERNANDEZ VALLADARES
ALFONSO RUBIO NAVARRO
MARIA PAZ DE LA ZAFRA MARTIN
DANIEL NIETO GARCIA
PABLO GRAVAN JIMENEZ
JUAN ANTONIO MARCHAL CORRALES
SAUL ABENHAMAR NAVARRO MARCHAL
JOSE LUIS PALACIOS FERRER
ANTONIO PALOMEQUE JIMENEZ
MANUEL PICON RUIZ
GLORIA RUIZ ALCALA
FRANCISCO JESUS ARREBOLA VARGAS
HOURIA BOULAIZ TASSI
ESMERALDA CARRILLO SLIM
MARIA EUGENIA GARCIA RUBIÑO
MARIA ANGEL GARCIA CHAVES
MICHAEL HACKENBERG
GEMA JIMENEZ GONZALEZ
ELENA LOPEZ RUIZ
MARGARITA AGUILERA GOMEZ
Degree: METHOD OF OBTAINING USEFUL DATA TO ASSESS THE RESPONSE TO TREATMENT WITH 5-FLUOROURACILO (5-FU)
Code: P201130247
Inventors: ARANEGA JIMENEZ ANTONIA; BOULAIZ HOURIA; CAMPOS ROSA JOAQUIN MARIA; CATIVIELA MARIN CARLOS; CHOQUESILLO-LAZARTE DUANE; RABBIT GARCIA ANA; CRUZ LOPEZ OLGA; GARCIA CHAVES MARIA ANGEL; GARCIA RUIZ JUAN MANUEL; JIMENEZ SANZ ANA ISABEL; MARCHAL
Degree: BENZOHETEROEPINE TARGETS
Code: P201030415
Inventors: A. Aránega; ALVAREZ DE MANZANEDA ROLDAN ENRIQUE; CHAHBOUN RACHID; F. Rodríguez Serrano; I. Messouri; H. Boulaiz; JA Marchal; C. Melguizo; M. Perán; J. Prados;
Degree: SYNTHETIC ANALOGS OF MEROSESQUITERPENES AND COMPOUNDS RELATED TO ANTI-TUMOR ACTIVITY
Code: P201050019
Inventors: Campos JM; Lopez l; Marchal JA; Boulaiz H; Aránega A; Rooster MA; Espinosa A; Rodríguez-Serrano F; Rabbit, Ana
Degree: NEW (RS) - 7- O 9- (1,2,3,5- TETRAHIDRO-4,1-BENZOCAZEPIN-3-IL) -7H O9H-PURINES WITH ANTI-TUMOR ACTIVITY
Code: P200802431
Inventors: ARANEGA JIMENEZ ANTONIA; CAMPOS ROSA JOAQUIN; ESPINOSA UBEDA ANTONIO; GALLO MEZO MIGUEL ANGEL; GOMEZ VIDAL JOSE ANTONIO; NUNEZ CARRETERO M DEL CARMEN; MARCHAL CORRALES JUAN ANTONIO; Rodriguez-Serrano F;
Degree: (2,3-DIHYDRO-5H-1,4-BENZODIHETEROEPIN-3-IL) PURINES WITH ANTI-TUMOR ACTIVITY
Code: P200601538
TGFß Governs the Pleiotropic Activity of NDRG1 in Triple-Negative Breast Cancer Progression
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2023;
FI: 9,2; Q1
Estradiol and Estrone Have Different Biological Functions to Induce NF-κB-Driven Inflammation, EMT and Stemness in ER plus Cancer Cells
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023;
FI: 6,208; Q1
Tigecycline reduces tumorigenesis in colorectal cancer via inhibition of cell proliferation and modulation of immune response
BIOMEDICINE & PHARMACOTHERAPY, 2023;
FI: 7,5; Q1
Interferon-Alpha Decreases Cancer Stem Cell Properties and Modulates Exosomes in Malignant Melanoma
CANCER, 2023;
FI: 5,2; Q2
Clinical implications of inflammation in atheroma formation and novel therapies in cardiovascular diseases
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2023;
FI: 5,5; Q2
Advances in spray products for skin regeneration
BIOACTIVE MATERIALS, 2022;
FI: 16,874; D1
Biofabrication approaches and regulatory framework of metastatic tumor-on-a-chip models for precision oncology
MEDICINAL RESEARCH REVIEWS, 2022;
FI: 12,388; D1
Chondro-Inductive b-TPUe-Based Functionalized Scaffolds for Application in Cartilage Tissue Engineering
ADVANCED HEALTHCARE MATERIALS, 2022;
FI: 11,092; D1
Evaluation of Phenolic Compounds and Pigments Content in Yellow Bell Pepper Wastes
ANTIOXIDANTS, 2022;
FI: 7,675; D1
EZH2 endorses cell plasticity to non-small cell lung cancer cells facilitating mesenchymal to epithelial transition and tumor colonization
ONCOGENE, 2022;
FI: 8,756; D1
Anti-CD44-Conjugated Olive Oil Liquid Nanocapsules for Targeting Pancreatic Cancer Stem Cells.
BIOMACROMOLECULES, 2021;
FI: 6,988; D1
Antioxidants for the Treatment of Breast Cancer: Are We There Yet?..
ANTIOXIDANTS, 2021;
FI: 6,313; D1
Cancer: a mirrored room between tumor bulk and tumor microenvironment
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2021;
FI: 11,161; Q1
Antimicrobial Effects of Potential Probiotics of Bacillus spp. Isolated from Human Microbiota: In Vitro and In Silico Methods.
MICROORGANISMS, 2021;
FI: 4,128; Q2
Acute Anisakiasis: Pharmacological Evaluation of Various Drugs in an Animal Model
DIGESTIVE DISEASES AND SCIENCES, 2021;
FI: 3,199; Q3
Bio-inspired hydrogel composed of hyaluronic acid and alginate as a potential bioink for 3D bioprinting of articular cartilage engineering constructs
BIOMATERIALIA ACT, 2020;
FI: 7,242; D1
Matrix metalloproteases and TIMPs as prognostic biomarkers in breast cancer patients treated with radiotherapy: A pilot study
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2020;
FI: 4,658; Q1
A combined healthy strategy for successful weight loss, weight maintenance and improvement of hepatic lipid metabolism
JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 2020;
FI: 4,873; Q1
A versatile theranostic nanodevice based on an orthogonal bioconjugation strategy for efficient targeted treatment and monitoring of triple negative breast cancer
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2020;
FI: 5,182; Q1
A Worldwide Overview of Regulatory Frameworks for Tissue-Based Products
TISSUE ENGINEERING PART B-REVIEWS, 2020;
FI: 6,089; Q1
Therapeutic strategies for skin regeneration based on biomedical substitutes
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019;
FI: 5,113; D1
A soft 3D polyacrylate hydrogel recapitulates the cartilage niche and allows growth-factor free tissue engineering of human articular cartilage
BIOMATERIALIA ACT, 2019;
FI: 6,638; D1
ADVANCES OF HYALURONIC ACID IN STEM CELL THERAPY AND TISSUE ENGINEERING, INCLUDING CURRENT CLINICAL TRIALS
EUROPEAN CELLS & MATERIALS, 2019;
FI: 3,682; D1
Catalytic and Electron Conducting Carbon Nanotube-Reinforced Lysozyme Crystals
ADVANCED FUNCTIONAL MATERIALS, 2019;
FI: 15,621; D1
New Platform for the Direct Profiling of microRNAs in Biofluids
ANALYTICAL CHEMISTRY, 2019;
FI: 6,35; D1
Exosome-Mediated Pathogen Transmission by Arthropod Vectors
TRENDS IN PARASITOLOGY, 2018;
FI: 7,929; D1
In-bioreactor ultrasonic monitoring of 3D culture human engineered cartilage
B-CHEMICAL SENSORS AND ACTUATORS, 2018;
FI: 5,667; D1
Activating Transcription Factor 4 Modulates TGF beta-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2 / 3/4 and mTORC2 Signaling
CLINICAL CANCER RESEARCH, 2018;
FI: 10,199; D1
Mesenchymal stem cell's secretome promotes selective enrichment of cancer stem-like cells with specific cytogenetic profile
CANCER LETTERS, 2018;
FI: 6,491; Q1
Albumin-covered lipid nanocapsules exhibit enhanced uptake performance by breast-tumor cells
COLLOIDS AND SURFACES B-BIOINTERFACES, 2018;
FI: 3,997; Q1
Obesity and Adverse Breast Cancer Risk and Outcome: Mechanistic Insights and Strategies for Intervention
CA-A CANCER JOURNAL FOR CLINICIANS, 2017;
FI: 187,04; D1
VEGFA links self-renewal and metastasis by inducing Sox2 to repress miR-452, driving Slug
ONCOGENE, 2017;
FI: 7,519; D1
Clinical and therapeutic potential of protein kinase PKR in cancer and metabolism
EXPERT REVIEWS IN MOLECULAR MEDICINE, 2017;
FI: 4,405; Q1
Poly (ethylmethacrylate-co-diethylaminoethyl acrylate) coating improves endothelial repopulation, bio-mechanical and anti-thrombogenic properties of decellularized carotid arteries for blood vessel replacement
SCIENTIFIC REPORTS, 2017;
FI: 4,259; Q1
Validation of suitable normalizers for miR expression patterns analysis covering tumor heterogeneity
SCIENTIFIC REPORTS, 2017;
FI: 4,259; Q1
Cancer suicide gene therapy: a patent review
EXPERT OPINION ON THERAPEUTIC PATENTS, 2016;
FI: 4,626; D1
Interactions between Adipocytes and Breast Cancer Cells Stimulate Cytokine Production and Drive Src / Sox2 / miR-302b-Mediated Malignant Progression
CANCER RESEARCH, 2016;
FI: 8,556; D1
Polymers, scaffolds and bioactive molecules with therapeutic properties in osteochondral pathologies: what's new?
EXPERT OPINION ON THERAPEUTIC PATENTS, 2016;
FI: 4,626; D1
Novel bead-based platform for direct detection of unlabelled nucleic acids through Single Nucleobase Labeling
TALANTA, 2016;
FI: 4,035; Q1
Low adherent cancer cell subpopulations are enriched in tumorigenic and metastatic epithelial-to-mesenchymal transition-induced cancer stem-like cells
SCIENTIFIC REPORTS, 2016;
FI: 5,228; Q1
5-Fluorouracil derivatives: a patent review (2012-2014)
EXPERT OPINION ON THERAPEUTIC PATENTS, 2015;
FI: 4,297; D1
Activin A / BMP2 chimera AB235 drives efficient redifferentiation of long term cultured autologous chondrocytes
SCIENTIFIC REPORTS, 2015;
FI: 5,578; D1
Amide-controlled, one-pot synthesis of tri-substituted slurries generates structural diversity and analogues with trypanocidal activity
SCIENTIFIC REPORTS, 2015;
FI: 5,578; D1
Balancing the effect of corona on therapeutic efficacy and macrophage uptake of lipid nanocapsules
BIOMATERIALS, 2015;
FI: 8,557; D1
Brown adipose tissue and novel therapeutic approaches to treat metabolic disorders
TRANSLATIONAL RESEARCH, 2015;
FI: 5,03; D1
Study of the prognostic and therapeutic value of the HSD17B family enzymes involved in estrone synthesis in patients with estrogen receptor-positive breast cancer
Funder: PUBLIC FOUNDATION FOR BIOSANITARY RESEARCH OF ORIENTAL ANDALUCIA ALEJANDRO OTERO (FIBAO)
File number: INTRAIBS-2022-07
Execution time: 20/01/2023 - 19/01/2024
IP: MANUEL PICON RUIZ
PROTEOMIC AND METABOLOMIC CHARACTERIZATION OF THE RESPONSE TO INTRAMUSCULAR INFUSION OF AUTOLOGOUS BONE MARROW STEM CELLS IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) FOR THE ESTABLISHMENT OF QUANTIFIABLE BIOMARKERS PREDICTIVE OF RESPONSE
Funder: UNIVERSITY OF GRANADA
File number: C-CTS-177-UGR23
Execution time: 01/01/2024 - 31/12/2026
IP: MARIA DEL CARMEN HERNANDEZ VALLADARES
Generation of a New Humanized Pompe Disease Model for Improved Robus Preclinical Evaluation of New Pompe Therapeutics
Funder: SPARK THERAPEUTICS, INC.
File number: SPARK-2022-0002
Execution time: 24/02/2023 - 24/02/2025
IP: FRANCISCO JAVIER MOLINA ESTEVEZ
Precision genetics to tackle pancreatic cancer chemoresistance
Funder: SPANISH ASSOCIATION AGAINST CANCER
File number: LABAE234749ZAFR
Execution time: 02/10/2023 - 01/10/2026
IP: MARIA PAZ DE LA ZAFRA MARTIN
Stem-Itruck: Next Generation Car-T Cells for the Safe and Effective Treatment of Solid Tumors
Funder: DEPARTMENT OF UNIVERSITY, RESEARCH AND INNOVATION
File number: ProyExcel_00373
Execution time: 01/01/2023 - 31/12/2025
IP: VERONICA AYLLON CASES
Generation of 4th generation inducible CAR-T cells for the treatment of HER2+ positive solid tumors.
Funder: CARLOS III HEALTH INSTITUTE - FEDER
File number: PMPTA22/00060
Execution time: 01/01/2023 - 31/12/2024
IP: FRANCISCO MARTIN MOLINA
Clinical impact of digital and 3D printed models based on CT and MRI fusion in pancreatic oncological surgery (DIGIPanCa)
Funder: STATE RESEARCH AGENCY
File number: TED2021-132438B-I00
Execution time: 01/12/2022 - 30/11/2024
PI: JUAN ANTONIO MARCHAL CORRALES
Spanish Network of Advanced Therapies (TERAV)
Funder: CARLOS III HEALTH INSTITUTE - FEDER
File number: RD21 / 0017/0004
Execution time: 01/01/2022 - 31/12/2024
IP: FRANCISCO MARTIN MOLINA
NABIHEAL – ANTIMICROBIAL NANOSTRUCTURED BIOMATERIALS FOR COMPLEX WOUND HEALING (NABIHEAL)
Funder: EUROPEAN COMMISSION
File number: 101092269
Execution time: 01/01/2023 - 31/12/2026
PI: JUAN ANTONIO MARCHAL CORRALES
Lymph and plasma extracellular vesicles as an alternative for the detection of mutations in breast cancer (BC-LinfaExOmic)
Funder: COUNCIL OF HEALTH AND FAMILIES
File number: PEMP-0205-2020
Execution time: 28/10/2021 - 27/10/2023
PI: JUAN ANTONIO MARCHAL CORRALES
Development and validation of a portable multimodular device for biomanufacturing and in situ repair of injured tissues (BioPen4Reg)
Funder: CARLOS III HEALTH INSTITUTE - FEDER
File number: DTS21 / 00098
Execution time: 01/01/2022 - 31/12/2023
PI: JUAN ANTONIO MARCHAL CORRALES
Development of decellularized biomimetic matrices with application in breast cancer models.
Funder: PUBLIC FOUNDATION FOR BIOSANITARY RESEARCH OF ORIENTAL ANDALUCIA ALEJANDRO OTERO (FIBAO)
File number: INTRAIBS-2020-10
Execution time: 01/01/2021 - 31/12/2021
IP: GEMA JIMENEZ GONZALEZ
HUMAN MICROBIOTA REFERENCE LABORATORY: Station for handling microorganisms in anaerobiosis and accessories for the optimization and harmonization of the phenotypic and genotypic analysis of the microbiota and its impact on nutrition and health.
Funder: COUNCIL OF ECONOMIC TRANSFORMATION, INDUSTRY, KNOWLEDGE AND UNIVERSITIES
File number: IE19_198 UGR
Execution time: 29/12/2020 - 29/12/2022
PI: MARGARITA AGUILERA GOMEZ
INFLUENCE OF ENDOCRINE DISRUPTERS CHEMICALS ON GUT MICROBIOTE: A MISSED LINK IN CHILDHOOD OBESITY (ENDOMICROMICS)
Funder: CARLOS III HEALTH INSTITUTE - FEDER
File number: PI20 / 01278
Execution time: 01/01/2021 - 31/12/2023
PI: MARGARITA AGUILERA GOMEZ
06-00001257-15 - FIPSE2015 - MARIA ANGEL GARCIA CHAVES - Method and means of isolation and enrichment of cancer stem cells with diagnostic and therapeutic utility in oncology
Funder: FOUNDATION FOR INNOVATION AND PROSPECTIVE IN HEALTH IN SPAIN
File number: 06-00001257-15
Execution time: 27/01/2016 - 26/07/2016
IP: MARIA ANGEL GARCIA CHAVES
Development of a Nanodiagnostic System Based on Myrnas / Exosomes Characteristic of Cancer Stem Cells with Prognostic and Predictive Value in Patients With Malignant Melanoma (Nanomir Melstem)
Funder: FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD
File number: PI-0533-2014
Execution time: 31/07/2015 - 01/08/2017
PI: JUAN ANTONIO MARCHAL CORRALES
PI-0441-2014 - Predictive Value of Pkr Kinase and Its Regulators in Patients With Metastatic Colon Cancer
Funder: FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD
File number: PI-0441-2014
Execution time: 01/08/2015 - 31/07/2017
IP: MARIA ANGEL GARCIA CHAVES
Drug development against tumor stem cells (CSCs) by screening synthetic libraries using GPCRs, kinases and the calcineurin-NFAT interaction as targets
Funder: MINISTRY OF ECONOMY AND COMPETITIVENESS
File number: RTC-2015-3386-1
Execution time: 01/09/2015 - 31/12/2017
PI: JUAN ANTONIO MARCHAL CORRALES
Prospective validation study of biomarkers of response to chemotherapy and therapies
Funder: CARLOS III HEALTH INSTITUTE - FEDER
File number: DTS15 / 00174
Execution time: 01/01/2016 - 31/12/2017
IP: MARIA ANGEL GARCIA CHAVES
Preclinical evaluation of safety and efficacy of a synthetic compound (MEGR756) and a compound of natural origin (MDN90) with selective activity against cancer stem cells
Funder: UNIVERSITY OF GRANADA
File number: UGR003 / B-16
Execution time: 01/01/2017 - 31/12/2018
PI: JUAN ANTONIO MARCHAL CORRALES
SMART OLIVE OIL NANOCAPSULES FOR ORAL ADMINISTRATION OF DRUGS AGAINST PANCREATIC CANCER STEM CELLS
Funder: MINISTRY OF ECONOMY AND COMPETITIVENESS
File number: MAT2015-63644-C2-2-R
Execution time: 01/01/2016 - 31/12/2018
PI: JUAN ANTONIO MARCHAL CORRALES
Potentiation of the action of ultrasound chemotherapy
Funder: UNIVERSITY OF GRANADA
File number: UGR002 / B-16
Execution time: 01/01/2017 - 31/12/2018
PI: JUAN ANTONIO MARCHAL CORRALES
HOKD TOXIN AS A NEW THERAPEUTIC TOOL AGAINST CANCER STEM CELLS DERIVED FROM PATIENTS WITH UTERAL CANCER
Funder: MUTUA MADRILEÑA FOUNDATION
File number: FMM-AP16683-2017
Execution time: 01/07/2017 - 31/12/2019
IP: HOURIA BOULAIZ TASSI
MUS4CT: Ultrasound Mechanotransduction for Improving Cancer Treatment
Funder: CARLOS III HEALTH INSTITUTE - FEDER
File number: DTS17 / 00087
Execution time: 01/01/2018 - 31/12/2019
PI: JUAN ANTONIO MARCHAL CORRALES
IMPLEMENTATION OF A NOVEL PLATFORM TO MONITOR TUMOR HETEROGENEITY AS A CRUCIAL DETERMINANT FOR INDIVIDUALIZED DIAGNOSTIC AND THERAPEUTIC OUTCOME
Funder: CARLOS III HEALTH INSTITUTE - FEDER
File number: PIE16 / 00045
Execution time: 01/01/2017 - 31/12/2019
PI: JUAN ANTONIO MARCHAL CORRALES
Development of bioprinting and biotin systems for three-dimensional cartilage and bone regeneration
Funder: MINISTRY OF ECONOMY AND COMPETITIVENESS
File number: RTC-2016-5451-1
Execution time: 01/01/2017 - 31/12/2019
PI: JUAN ANTONIO MARCHAL CORRALES
Development of a New Gene Therapy Tool Based on the Use of Ldrb Toxin Targeting Cancer Stem Cells Derived from Breast and Colon Cancer Patients.
Funder: COUNCIL OF HEALTH
File number: PI-0089-2017
Execution time: 01/01/2018 - 31/12/2020
IP: HOURIA BOULAIZ TASSI
BIOINKS 4 3D-SKIN: New biotinks for 3D bioprinting of skin grafts and malignant melanoma models
Funder: CARLOS III HEALTH INSTITUTE - FEDER
File number: DTS19 / 00143
Execution time: 01/01/2020 - 31/12/2021
PI: JUAN ANTONIO MARCHAL CORRALES
OBEMIRISK-Knowledge platform for assessing the risk of Biosphenols on gut microbiota and its role in obesogenic phenotype: looking for biomarkers,
Funder: EFSA EUROPEAN FOOD SAFETY AUTHORITY
File number: GP / EFSA / ENCO / 2018/03 - GA04
Execution time: 05/12/2018 - 01/05/2021
PI: MARGARITA AGUILERA GOMEZ
OncoBreast3DPrint: BIOPRINTED MIMETIC TUMOR MODELS OF BREAST CANCER USEFUL IN PRECISION ONCOLOGY
Funder: COUNCIL OF HEALTH AND FAMILIES
File number: PIN-0224-2019
Execution time: 01/01/2020 - 31/12/2022
IP: GEMA JIMENEZ GONZALEZ
IDENTIFICATION OF THE PATHOPHYSIOLOGICAL ROLE OF THE MICROBIOTA ALTERED BY DIETARY XENOBIOTICS IN PATIENTS WITH HORMONAL DISORDERS - REFERENCE LABORATORY
Funder: MINISTRY OF SCIENCE, INNOVATION AND UNIVERSITIES
File number: EIN2019-103082
Execution time: 01/11/2019 - 30/06/2021
PI: MARGARITA AGUILERA GOMEZ
RESEARCH INTENSIFICATION ACTIONS WITHIN THE EUROPEAN PROJECT: EFSA PARTNERING GRANT-GA04: OBEMIRISK
Funder: UNIVERSITY OF GRANADA
File number: INT-14
Execution time: 01/11/2019 - 30/06/2021
PI: MARGARITA AGUILERA GOMEZ
3D bioprinting of cartilage and bone with decellularized matrix-based biotin (dECM) for the regeneration of osteochondral lesions
Funder: MUTUA MADRILEÑA FOUNDATION
File number: FMM-AP17196-2019
Execution time: 01/07/2019 - 30/06/2022
PI: ELENA LOPEZ RUIZ